)
Edge10 Jul 2026
Inside Take-Two: The Grand Anticipation
The story of how Take-Two Interactive built the empire behind Grand Theft Auto, Red Dead Redemption, and one of gaming's largest mobile portfolios.
Impact BioMedical
Impact BioMedical (IBO) investor relations material
Impact BioMedical Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary7 Aug, 2026
Executive summary
Focused on developing and licensing proprietary healthcare and wellness technologies, with ongoing efforts to monetize intellectual property and control costs.
Principal subsidiaries include Global BioLife, Impact BioLife Science, Global BioMedical, and Sweet Sense.
Key technologies in development: Linebacker (oncology/inflammation), Laetose (metabolic health), 3F (functional fragrances), and Equivir (antiviral supplement).
Financial highlights
Revenue for Q2 2026 was $3,000, down 57% year-over-year; six-month revenue was $10,000, up 43% from prior year.
Net loss for Q2 2026 was $700,000, a 95% improvement year-over-year; six-month net loss was $2,983,000, down 81%.
Total assets as of June 30, 2026 were $16.7 million, with $10,000 in cash and $16.4 million in intangible assets.
Stock-based compensation for the six months ended June 30, 2026 was $1,440,000.
Outlook and guidance
Management is exploring capital raises and debt financing to address going concern risks.
Plans include monetizing intellectual property and tightly controlling operating costs.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Impact BioMedical
- Net loss widened to $2.3M in Q1 2026 amid minimal revenue and high stock-based compensation.IBO
Q1 202612 May 2026 - Net loss narrowed to $11.87M as IP expanded and $15M debt was converted to equity.IBOQ4 202511 Mar 2026
- Annual meeting to elect directors, ratify auditor, and approve executive pay, with DSS holding control.IBOProxy Filing2 Dec 2025
- Biomedical IP firm seeks $3–$5/share in IPO to fund R&D and commercialization amid ongoing losses.IBORegistration Filing29 Nov 2025
- Biomedical IP firm with no revenue, high risk, and IPO proceeds aimed at R&D and commercialization.IBORegistration Filing29 Nov 2025
- Firm commitment IPO with Revere Securities, LLC as underwriter and experienced governance.IBORegistration Filing29 Nov 2025
- Public offering planned with $252,000 in estimated expenses and a defined executive team.IBORegistration Filing29 Nov 2025
- Significant net loss, limited revenue, IPO completed, and major merger planned for Q1 2026.IBOQ3 20257 Nov 2025
- Q2 2025 saw a sharp net loss increase, minimal revenue, and major strategic transactions.IBOQ2 202514 Aug 2025
Next Impact BioMedical earnings date
Q3 20266 Nov, 2026
Impact BioMedical
Next Impact BioMedical earnings date
Q3 20266 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage